#USA #Costa Mesa #FDA Breakthrough #NET Recovery #addiction technology

NET Recovery Achieves FDA Breakthrough Device Designation

In a groundbreaking development, NET Recovery, a company on the forefront of addiction treatment, has announced that the U.S. Food and Drug Administration (FDA) has awarded it the Breakthrough Device Designation for their NET Device™. This designation is a significant milestone, especially considering that there are currently no FDA-approved drugs or medical devices available for the treatment of stimulant use disorders, including cocaine and methamphetamine addiction.

Addressing a Dire Need

According to the Centers for Disease Control and Prevention (CDC), approximately 4.5 million individuals in the United States are grappling with the dual challenges of opioid and stimulant use. Alarmingly, over half of U.S. overdose deaths from January 2021 to June 2024 involved stimulants, highlighting the urgent need for effective treatment options. Unlike opioid use disorder, which has a range of FDA-approved therapies, stimulant use disorder remains largely untreated, leaving countless individuals in distress without acceptable options.

NET Recovery's CEO, Joe Winston, highlighted the organization’s commitment to changing this narrative. He stated, "There are millions of people suffering without any approved treatment options for stimulant use disorder, and this Breakthrough Device Designation brings us one step closer to helping change that with a device that does not require the use of drugs." The sentiment underscores the long-standing need for innovative solutions that go beyond traditional pharmacological treatments.

Innovative Treatment Approach

The NET Device operates as a transcutaneous alternating current stimulator (tACS), which has already received FDA clearance for managing opioid withdrawal symptoms in combination with standard medications. The new breakthrough designation expands its intended use to include reducing the impact of stimulant use disorders in adults aged 18 and older. This innovative device has the potential to transform lives by providing a non-drug-related treatment option for those struggling with addiction.

While currently not authorized for treating stimulant use disorder, NET Recovery is actively designing a pivotal randomized controlled trial. This study aims to secure FDA marketing authorization through what is anticipated to be a De Novo review pathway, reflecting the company’s dedication to bringing this vital resource to those in need.

Moving Towards Real Solutions

Winston emphasized the urgency and importance of their mission, stating, "We're focused on proving that a non-pharmacological approach can deliver real change for people struggling with stimulant use disorder." The vision for NET Recovery is not only to address the immediate crisis but also to genuinely redefine addiction treatment in a way that respects the dignity and rights of individuals seeking help.

As the organization moves forward, industry experts and advocates are watching closely. If successful, the NET Device could represent a significant advance in addiction treatment, potentially providing hope where there has been little before. The focus is now on creating a world where those affected by stimulant use disorder have access to safe, effective options that empower their recovery journey.

Conclusion

In a landscape where treatment options for stimulant addiction have been dismally scarce, NET Recovery’s recent FDA Breakthrough Device Designation not only offers a glimmer of hope but also paves the way for future changes in how addiction is managed. As the realities of addiction continue to evolve, innovative companies like NET Recovery are key players in the quest for practical solutions—reminding us that the fight against addiction is an urgent imperative.

For more information about the innovative work being done by NET Recovery, interested parties are encouraged to visit their official website at NET Recovery.